share_log

In8bio | D: Filing D

SEC announcement ·  Dec 28, 2023 00:00
Summary by Moomoo AI
In8bio, Inc., a biotechnology company incorporated in Delaware and based in New York, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice of securities offering. The filing, dated December 28, 2023, reports that the company has successfully raised $14,425,013 USD through the sale of equity and securities with options or warrants. The offering, which commenced on December 13, 2023, did not last more than a year and has been completed with the total offering amount sold. The company has claimed an exemption under Rule 506(b) and has not disclosed the use of proceeds for payments to any executive officers, directors, or promoters. The filing also notes that sales commissions totaling $643,470 USD were paid in connection with the offering. The company's executive officers and directors, including Chief Financial Officer Patrick McCall, are listed in the filing. In8bio has not made this offering in connection with a business combination transaction and has not accepted any investment from non-accredited investors.
In8bio, Inc., a biotechnology company incorporated in Delaware and based in New York, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice of securities offering. The filing, dated December 28, 2023, reports that the company has successfully raised $14,425,013 USD through the sale of equity and securities with options or warrants. The offering, which commenced on December 13, 2023, did not last more than a year and has been completed with the total offering amount sold. The company has claimed an exemption under Rule 506(b) and has not disclosed the use of proceeds for payments to any executive officers, directors, or promoters. The filing also notes that sales commissions totaling $643,470 USD were paid in connection with the offering. The company's executive officers and directors, including Chief Financial Officer Patrick McCall, are listed in the filing. In8bio has not made this offering in connection with a business combination transaction and has not accepted any investment from non-accredited investors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more